Previous 10 | Next 10 |
Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest treatment benefit in major adverse cardiovascular events (MACE) of cardiovascular mor...
Mesoblast (NASDAQ:MESO): Q1 GAAP EPS of -$0.03 beats by $0.10. Revenue of $3.6M (+176.9% Y/Y) beats by $1.21M. Press Release Revenues from TEMCELL® HS Inj. royalties in Japan were $2.4 million, an increase of 22% on the previous quarter, and of 90% on the comparative ...
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the first quarter ended September 30, 2021. “We are pl...
Mesoblast (NASDAQ:MESO) has successfully refinanced its existing senior debt facility with a new $90M five year facility provided by funds managed by Oaktree Capital Management, L.P. Mesoblast drew the first tranche of $60M on closing, with proceeds being used to repay the outstanding balance...
Mesoblast (NASDAQ:MESO) announces results from the Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF) at the American Heart Association (AHA) annual Scientific Sessi...
Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for...
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results published in the latest issue of the peer-reviewed journal Bone Marrow Transplantation 1 showe...
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart ...
The S&P 500 and the Nasdaq managed to eke out thin gains on Wednesday despite weakness in certain parts of the oil-production and refining sectors. Devon Energy (NYSE:DVN), Marathon Oil (NYSE:MRO), Valero Energy (NYSE:VLO) and APA Corp. (NASDAQ:APA) all showed weakness during the session ...
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...